SCHEMBL7097300

SCHEMBL7097300

CCCCC(CC)COC(=O)CC(=O)c1ccco1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.52
CYP3A4 P08684 3/20 0.52
CA2 P00918 1/20 0.52
TSHR P16473 5/20 0.51
TDP1 Q9NUW8 2/20 0.51
ATM Q13315 1/20 0.51
LMNA P02545 3/20 0.48
PRSS1 P07477 1/20 0.47
PRSS2 P07478 1/20 0.47
PRSS3 P35030 1/20 0.47
MAPK1 P28482 3/20 0.45
HSD17B10 Q99714 1/20 0.44
RECQL P46063 1/20 0.44
HDAC3 O15379 1/20 0.43
ERCC5 P28715 1/20 0.43
FEN1 P39748 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12368062 0.85 ALDH1A1 (0.64) ALDH1A1CYP3A4CA2TSHRTDP1
SCHEMBL1201268 0.80 ALDH1A1 (0.60) ALDH1A1CYP3A4CA2TSHRTDP1
SCHEMBL5162808 0.78 ALDH1A1 (0.50) ALDH1A1CYP3A4CA2TSHRTDP1
SCHEMBL5160710 0.78 CYP3A4 (0.51) ALDH1A1CYP3A4CA2TSHRTDP1
SCHEMBL1126497 0.77 ERCC5 (0.56) ALDH1A1TSHRTDP1LMNAHSD17B10
SCHEMBL2215691 0.77 CYP3A4 (0.77) ALDH1A1CYP3A4CA2TSHRTDP1
SCHEMBL19024941 0.77 ALDH1A1 (0.63) ALDH1A1CYP3A4CA2TSHRTDP1
SCHEMBL5160657 0.76 CYP3A4 (0.55) ALDH1A1CYP3A4CA2TSHRTDP1
SCHEMBL1200573 0.76 CYP3A4 (0.55) ALDH1A1CYP3A4CA2TSHRTDP1
SCHEMBL5160040 0.76 ALDH1A1 (0.53) ALDH1A1CYP3A4CA2TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ALDH1A1 273/4885CYP3A4 7/4885CA2 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.